Ofichem Group has agreed to acquire Avivia B.V., a company specialized in formulation development based in Nijmegen, the Netherlands. The acquisition marks a significant step in Ofichem’s strategy to become a fully integrated provider of development solutions across drug substance and drug product, with a focus on complex formulations.

Avivia is a Contract Development Organization (CDO) with expertise in formulation development, analytical method development, dissolution testing, and excipient characterization. The acquisition will strengthen Ofichem’s integrated development offering, enabling the group to offer broader, deeper support from early-phase development through to GMP production.

“By integrating Avivia into the Ofichem Group, we are strengthening our ability to support customers from drug substance through R&D and small to large scale GMP manufacturing and reinforcing our commitment to innovation and customer-centricity,” said Dr. Weite H. Oldenziel, CEO and owner of the Ofichem Group. “This acquisition complements our capabilities in Ter Apel and Leiden and enables us to offer broader, more integrated services to our global customers.”

“This move further supports our ambition to evolve as a science-led CDMO and deliver innovation-driven solutions to our customers with enhanced capability in solving complex formulation challenges,” Weite added. “We’re excited to welcome Avivia’s talented team into the Ofichem Group.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.